(Q34436986)
Statements
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer (English)
Roy S Herbst
Diane Prager
Robert Hermann
Lou Fehrenbacher
Bruce E Johnson
Alan Sandler
Hai T Tran
Pam Klein
Xin Li
David Ramies
David H Johnson
Vincent A Miller
TRIBUTE Investigator Group